Furthermore, RIPK1 inhibition reduced the number of microglia in a state referred to as RIPK1-regulated inflammatory microglia (RRIM) that produce pro-inflammatory cytokines in ALS mice, suggesting that RIPK1 inhibitors could be a potential ALS therapy [45]. This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.